Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
Qamar J. Khan(University of Kansas Medical Center), Priyanka Sharma(Chandigarh University), Laura M. Spring(Massachusetts General Hospital), Mohammad Jahanzeb(Florida Atlantic University), Anne O’Dea(University of Kansas Medical Center), Amanda L. Amin(University of Kansas Medical Center), Aditya Bardia(UCLA Health), Mia Hard(The University of Kansas Cancer Center), X. Cynthia(Washington University in St. Louis), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Jamie L. Wagner(University of Kansas Medical Center), Gregory Crane(University of Kansas Medical Center), Meghna S. Trivedi(Columbia University), Sibel Blau(University of Washington Tacoma), Ruth O’Regan(University of Wisconsin Carbone Cancer Center), Onalisa Winblad(University of Kansas Medical Center), Yuan Yuan(Cedars-Sinai Medical Center), Issam Makhoul(University of Arkansas for Medical Sciences), Manana Elia(University of Kansas Medical Center), Kevin Kalinsky(Emory University)
Cited by 68
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k